Atypical antipsychotics in Parkinson-sensitive populations

Area of Science:

• Neurology
• Psychiatry
• Geriatrics

Background:

• Drug-induced psychosis and hallucinations affect ~30% of Parkinson's disease (PD) patients, often leading to nursing home placement.
• Parkinsonism frequently co-occurs with dementia syndromes like Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
• Atypical antipsychotics (AA) were developed for schizophrenia with fewer motor side effects, but their use in PD populations is a critical test.

Purpose of the Study:

• To review and compare the motor effects of four atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine) in parkinson-vulnerable populations.
• To highlight the challenges in interpreting existing data on AA motor effects, particularly in non-PD elderly and cognitively impaired individuals.

Main Methods:

• Review of existing studies on clozapine, risperidone, olanzapine, and quetiapine in patients with PD or parkinsonism.
• Analysis of reported motor side effects and differences among these four AA drugs.

Main Results:

• The four reviewed atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine) exhibit varying impacts on motor function in PD patients.
• Significant challenges exist in evaluating the motor effects of AAs in the elderly and cognitively impaired, complicating direct comparisons.

Conclusions:

• Understanding the differential motor effects of AAs is crucial for managing psychosis in PD and related disorders.
• Further research is needed to improve the interpretability and standardization of studies evaluating AA motor effects in vulnerable patient groups.